SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients.

- AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue - - ...

AMT-101 is the only oral gastrointestinal-targeted IL-10 biologic designed to be actively transported through the intestinal epithelium barrier into the GI tissue, the primary site of inflammation in ...

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT ...

The objectives of the FILLMORE trial were to assess the safety and efficacy of AMT-101 in severe chronic pouchitis patients and to select a dose for Phase 3. The trial was designed to measure two key ...

New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological ...

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the first patient has ...